The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy

Diabetes is a major cause of visual impairment among working-age adults in the United States. The proliferative form of diabetic retinopathy is associated with severe vision loss (acuity <5/200). The standard treatment in proliferative diabetic retinopathy (PDR) is panretinal photocoagulation (PR...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Drugs in Context Ročník 7; s. 212532 - 10
Hlavní autoři: Zhao, Yue, Singh, Rishi P
Médium: Journal Article
Jazyk:angličtina
Vydáno: England BioExcel Publishing Ltd 13.08.2018
Témata:
aflibercept
angiogenesis inhibitors
antibodies
bevacizumab
diabetic retinopathy
humanized antibodies
intravitreal injection
monoclonal
ranibizumab
Review
vascular endothelial growth factor A
aflibercept
bevacizumab
antibodies
monoclonal
intravitreal injection
angiogenesis inhibitors
diabetic retinopathy
vascular endothelial growth factor A
humanized antibodies
ranibizumab
ISSN:1745-1981, 1740-4398, 1740-4398
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Diabetes is a major cause of visual impairment among working-age adults in the United States. The proliferative form of diabetic retinopathy is associated with severe vision loss (acuity <5/200). The standard treatment in proliferative diabetic retinopathy (PDR) is panretinal photocoagulation (PRP), which is effective but has established side effects such as peripheral visual-field constraints. Vascular endothelial growth factor (VEGF) is thought to drive the process of vascular proliferation. Drugs targeting VEGF (anti-VEGF) have been studied extensively in diabetic macular edema (DME), and results have shown that diabetic retinopathy regresses with anti-VEGF treatment. Recent studies show that anti-VEGF is not inferior to PRP for PDR while treatment is maintained, though recurrence rate when anti-VEGF treatment is stopped is unclear. In vitreous hemorrhage where PRP cannot be performed, use of anti-VEGF medications can treat underlying PDR and delay or reduce need for vitrectomy. Limitations of anti-VEGF treatment, however, require careful patient selection and monitoring. This review discusses recent clinical trials and guidelines for anti-VEGF use in PDR.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1745-1981
1740-4398
1740-4398
DOI:10.7573/dic.212532